Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.

Abstract:

:Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity. Controlled studies and clinical experience have shown that it possesses anorectic activity at least as good as that of other therapeutically useful drugs of its type, but like these drugs it has only a limited role in the overall management of obesity. Tolerance to the anorectic effects of fenfluramine may possibly develop more slowly than to other chemically related drugs in patients with refractory obesity. The mechanism of its anorectic action is probably by an effect on the appetite control centres in the hypothalamus, rather than by an effect on glucose and lipid metabolism. However, its effect in enhancing glucose uptake into skeletal muscle may be of advantage in diabetes mellitus, preliminary studies suggesting that it is of potential use in maturity-onset obese diabetics who cannot be adequately controlled by dietary measures alone. The starting dosage in obesity of 40mg daily should be increased gradually over 2 to 4 weeks to 60 to 120mg. In general, little extra benefit is gained by higher dosage. When a course of therapy is to be discontinued, fenfluramine dosage should be reduced gradually over a period of 2 to 4 weeks in order to avoid mood depression which has occurred in some patients on abrupt withdrawal of the drug. With these recommendations, the majority of patients tolerate fenfluramine satisfactorily, although some patients may have to discontinue the drug because of troublesome gastro-intestinal problems, diarrhoea, drowsiness or dizziness. Unlike other amphetamine-derived anorectics, fenfluramine is not a central stimulant in therapeutic doses, and it probably has little abuse potential.

journal_name

Drugs

journal_title

Drugs

authors

Pinder RM,Brogden RN,Sawyer PR,Speight TM,Avery GS

doi

10.2165/00003495-197510040-00001

subject

Has Abstract

pub_date

1975-01-01 00:00:00

pages

241-323

issue

4

eissn

0012-6667

issn

1179-1950

journal_volume

10

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Postmenopausal hormone replacement therapy and cardiovascular risk reduction. A review.

    abstract::Administration of unopposed postmenopausal estrogen therapy protects against coronary heart disease (CHD) in women. This is mediated, in part, through beneficial effects on lipid and lipoprotein metabolism. Fewer data are available with regard to CHD risk reduction when a progesterone is required in addition to estrog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400472-00005

    authors: Kafonek SD

    更新日期:1994-01-01 00:00:00

  • Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia.

    abstract::Pentamidine is an aromatic diamidine derivative which has become one of the standard therapies for Pneumocystis carinii pneumonia (PCP), particularly in patients with acquired immunodeficiency syndrome (AIDS). However, with parenteral administration of the drug there is a high risk of toxicity. Inhaled pentamidine pro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199039050-00008

    authors: Monk JP,Benfield P

    更新日期:1990-05-01 00:00:00

  • Tacrolimus: in patients with rheumatoid arthritis.

    abstract::Tacrolimus, a hydrophobic macrolide with immunosuppressant properties, has recently been evaluated as a new treatment for adults with active rheumatoid arthritis. Oral tacrolimus 3mg once daily was significantly more effective than placebo in patients with rheumatoid arthritis (RA) who were refractory or intolerant to...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565070-00005

    authors: Curran MP,Perry CM

    更新日期:2005-01-01 00:00:00

  • Enasidenib: First Global Approval.

    abstract::Enasidenib (Idhifa®) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under a global, exclusive license from Agios Pharmaceuticals. Enasidenib has been approved in the USA for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) and an IDH2 mutation a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0813-2

    authors: Kim ES

    更新日期:2017-10-01 00:00:00

  • Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

    abstract::The development of chronic heart failure (CHF) includes phenotypic changes in a host of homeostatic systems so that, as the disease advances, CHF may be seen as a multi-system disorder with its origins in the heart but embracing many extra-cardiac manifestations. Immunological abnormalities are recognised in this cont...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060060-00002

    authors: Bolger AP,Anker SD

    更新日期:2000-12-01 00:00:00

  • Prediction of response to cancer chemotherapy.

    abstract::Cytotoxic chemotherapy plays a key role in the treatment of carcinoma for thousands of patients annually who either present with metastatic disease or relapse after surgical excision of apparently localised disease. Unfortunately, there is such a wide range of responsiveness to drug therapy within individual tumour ty...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198326050-00004

    authors: Sarosdy MF,Von Hoff DD

    更新日期:1983-11-01 00:00:00

  • Lung tissue penetration of temocillin.

    abstract::Eight patients about to have the whole or part of a lung resected were given a 2g bolus dose of temocillin. A series of serum samples and a piece of peripheral lung tissue were collected and assayed for temocillin concentration. 30 minutes after drug administration, the mean serum and tissue concentrations were 172 mg...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00031

    authors: Cowan W,Baird A,Sleigh JD,Gray JM,Leiper JM,Lawson DH

    更新日期:1985-01-01 00:00:00

  • Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

    abstract::Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. The drug is active against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae but not Staphylococcus aureus. Cefixime has a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549060-00010

    authors: Markham A,Brogden RN

    更新日期:1995-06-01 00:00:00

  • New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.

    abstract::Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conven...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0301-x

    authors: Dobesh PP,Fanikos J

    更新日期:2014-11-01 00:00:00

  • Inflammatory bowel disease management. Some thoughts on future drug developments.

    abstract::This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753020-00001

    authors: Rhodes J,Thomas G,Evans BK

    更新日期:1997-02-01 00:00:00

  • Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

    abstract::Certolizumab pegol (Cimzia(®)) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor (TNF)-α. The drug is indicated for subcutaneous use every 2 or 4 weeks (q2w or q4w) for the treatment of adults with mo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0009-3

    authors: Deeks ED

    更新日期:2013-01-01 00:00:00

  • Influence of fibrinogen on cardiovascular disease.

    abstract::Results from prevalence, case-control, angiographic and echocardiographic investigations incriminate elevated fibrinogen levels as a strong independent risk factor for the occurrence of initial and recurrent cardiovascular events. Average fibrinogen levels are higher in women and persons with other risk factors includ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700543-00006

    authors: Kannel WB

    更新日期:1997-01-01 00:00:00

  • Drug treatment of haemorrhoids.

    abstract::Drug treatment for various anorectal conditions has been known since ancient times. Today, modern as well as traditional drugs are being increasingly used in all grades of symptomatic haemorrhoids. These drugs (oral and local) are used as a part of conservative management or as an adjuvant to invasive outpatient proce...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565110-00003

    authors: Misra MC,Imlitemsu

    更新日期:2005-01-01 00:00:00

  • Effects of ketanserin tartrate on serum lipids in patients with essential hypertension.

    abstract::Several antihypertensive agents such as thiazide diuretics and some beta-blockers have recently been shown to adversely affect lipid metabolism. Moreover, there is a growing suspicion that the adverse effect on plasma lipids might outweigh the favourable effect of lowering blood pressure. The effect of ketanserin tart...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198800361-00006

    authors: Nakamura H,Hirata F,Yasugi T,Mizuno M,Saito E,Ishikawa T,Tada N,Nakaya N,Homma Y,Takeuchi I

    更新日期:1988-01-01 00:00:00

  • Appropriate use of antitussives and protussives. A practical review.

    abstract::As a symptom of an underlying condition, cough is one of the most common reasons patients see physicians. To the majority, a cough means that 'something is wrong' and it causes exhaustion and/or self-consciousness. Patients find these reasons as well as effects on lifestyle, fear of cancer and/or AIDS or tuberculosis ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346010-00006

    authors: Irwin RS,Curley FJ,Bennett FM

    更新日期:1993-07-01 00:00:00

  • An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes.

    abstract::Arachidonic acid is normally stored in membrane-bound phospholipids and released by the action of phospholipases. Enzymatic conversion of released arachidonic acid into biologically active derivatives proceeds through one of several routes. Cyclo-oxygenase converts arachidonic acid to unstable cyclic endoperoxides fro...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700331-00003

    authors: Samuelsson B

    更新日期:1987-01-01 00:00:00

  • The prevalence of hypertension in the United States today.

    abstract::The simplest response to the question, what is the prevalence of hypertension in the United States today?, is given by a currently popular slogan: 23,000,000 Americans have hypertension. It is clear that the problem is large in scale, but this figure alone is an insufficient guide to many practical issues. The prevale...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197600111-00006

    authors: Labarthe DR

    更新日期:1976-01-01 00:00:00

  • Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium.

    abstract::Iodixanol is an iso-osmolal nonionic dimeric hydrophilic contrast agent. It has similar diagnostic efficacy to that of other iodinated contrast media. Because of its physical properties, iodixanol would be expected to produce a lower incidence of adverse events than other nondimeric contrast media. Indeed, pharmacodyn...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652060-00013

    authors: Spencer CM,Goa KL

    更新日期:1996-12-01 00:00:00

  • Issues in patient compliance.

    abstract::Patient compliance refers to the willingness and ability of an individual to follow health-related advice, to take medication as prescribed, to attend scheduled clinic appointments and to complete recommended investigations. It is a major health issue, with outcomes related to levels of morbidity, mortality and cost u...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754060-00002

    authors: Murphy J,Coster G

    更新日期:1997-12-01 00:00:00

  • Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation.

    abstract::Transdermal nicotine delivery systems are a cigarette smoking cessation aid designed to deliver nicotine into the systemic circulation via the skin. The partial replacement of plasma nicotine, which would have otherwise been obtained from cigarettes, reduces the severity of nicotine withdrawal symptoms, and so allows ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199244030-00011

    authors: Palmer KJ,Buckley MM,Faulds D

    更新日期:1992-09-01 00:00:00

  • Prospects for the development of new treatments with a rapid onset of action in affective disorders.

    abstract::Several compounds have been claimed to have a faster onset of antidepressant action. However, these trials suffered from lack of appropriate definitions and of standardised and comparable methodology, as far as measurement instruments, dosage strategies and statistical analyses were concerned. This article was underta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652040-00001

    authors: Soares JC,Gershon S

    更新日期:1996-10-01 00:00:00

  • Studies with temocillin in the hamster model of antibiotic-associated colitis.

    abstract::The studies reported here were designed to ascertain whether or not the new beta-lactam antibiotic, temocillin, would produce antibiotic-associated colitis in the hamster. The experiments were controlled with clindamycin and cefoxitin, which are known to induce antibiotic-associated colitis experimentally and clinical...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00012

    authors: Boon RJ,Beale AS

    更新日期:1985-01-01 00:00:00

  • A comparison of roxatidine acetate and ranitidine in gastric ulcer healing.

    abstract::A randomised multicentre double-blind study was conducted to compare the efficacy and safety of roxatidine acetate 75 mg twice daily and ranitidine 150 mg twice daily in 295 patients with endoscopically confirmed gastric ulcers. Substantial reductions in ulcer diameters and healing rates of 85.6 and 88.2% for roxatidi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800353-00021

    authors: Judmaier G

    更新日期:1988-01-01 00:00:00

  • Uraemic pruritus: clinical characteristics, pathophysiology and treatment.

    abstract::Pruritus is a common complication of end-stage renal disease (ESRD), affecting about one-third of dialysis patients. It is a chronic, unpleasant symptom with a strong negative impact on patients' quality of life, often inducing sleeplessness and mood disorders. Recent data show that it is also associated with increase...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969030-00002

    authors: Manenti L,Tansinda P,Vaglio A

    更新日期:2009-01-01 00:00:00

  • [Pain management: health economics and quality of life considerations].

    abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Phillips CJ

    更新日期:2003-01-01 00:00:00

  • Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

    abstract:UNLABELLED:Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity and has demonstrated a lack of cross-resistance with other platinum compounds. In patients with metastatic colorectal cancer, intrav...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060040-00005

    authors: Culy CR,Clemett D,Wiseman LR

    更新日期:2000-10-01 00:00:00

  • Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.

    abstract::Enalapril provides significant haemodynamic, symptomatic and clinical improvement when added to maintenance therapy with digitalis and diuretics in patients with congestive heart failure [NYHA (New York Heart Association) classes II to IV]. These effects are not attenuated during long term therapy. More significantly,...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198937020-00004

    authors: Todd PA,Goa KL

    更新日期:1989-02-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

    abstract::When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors. Animal studies have demonstrated that entacapone ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059060-00004

    authors: Kaakkola S

    更新日期:2000-06-01 00:00:00

  • Acute upper gastrointestinal bleeding.

    abstract::The treatment of acute upper gastrointestinal bleeding is becoming more dependent upon early diagnosis. For the majority of patients whose bleeding has stopped when they come to the physician's attention, treatment for peptic disorders remains the mainstay of therapy. For patients who present to the physician actively...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198937010-00007

    authors: Schaffner JA

    更新日期:1989-01-01 00:00:00